Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Orelabrutinib combined with bendamustine-rituximab or obinutuzumab followed by orelabrutinib maintenance in untreated marginal zone lymphoma (Optimize): A multicenter, single-arm, phase II study

View Full Paper
Ask AI
Bookmark
Share

Authors

XYXingnong YeCYChunmei YangWXWanzhuo Xie

Discussion

Loading...

Member takes

Overview

Phase II study demonstrates improved progression-free survival with bendamustine-rituximab or obinutuzumab in untreated marginal zone lymphoma, indicating a promising treatment option.

Key Points

  • A complete response rate of 75% was observed in group A and 66.7% in group B after induction treatment with orelabrutinib.
  • The overall objective response rate reached 93.3%, showing significant efficacy of the treatment regimen across patients with marginal zone lymphoma.
  • Observational analysis across 7 centers evaluated the effectiveness of orelabrutinib combined with bendamustine-rituximab or obinutuzumab.
  • The study highlights the need for continued monitoring as safety concerns related to adverse events were noted in 43.7% of patients overall.

Cite This Study

Ye et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da10https://doi.org/10.1182/blood-2025-3596
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy, safety, and NGS analysis of orelabrutinib combined with obinutuzumab in untreated marginal zone lymphoma2025
  2. 2Preliminary study results of orelabrutinib in combination with rituximab for treatment-Naïve marginal zone lymphoma: A prospective single-arm clinical trial2025 · 1 citations
  3. 3Preliminary analysis of orelabrutinib combined with obinutuzumab in the treatment of marginal zone lymphoma (Orion Study)2025
  4. 4Real-world efficacy and safety of orelabrutinib-based regimens in the treatment of marginal zone lymphoma2025
  5. 5Efficacy and safety of first-line orelabrutinib combined with obinutuzumab (With or Without Bendamustine) in high-risk marginal zone lymphoma: Results from the orchid study2025